On Nov. 6, 2020, Humanigen announced that it had entered into a Cooperative Research and Development Agreement (CRADA) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), to help meet the federal governmentﾒs Operation Warp Speed goals. The agreement supported development of lenzilumab in advance of a potential Emergency Use Authorization (EUA) for COVID-19.

The CRADA aimed to support the ongoing lenzilumab Phase 3 clinical trials, focusing on efficiently generating EUA and BLA submissions.